AstraZeneca PLC Stock Performance
AstraZeneca PLC shares have demonstrated significant upward momentum across multiple timeframes, trading at $186.43 per SID market data. The stock has gained 17.41% over the past month and 15.14% over three months, while the one-year return stands at an impressive 127.27%. AZN currently trades well above both its 50-day moving average of $166.47 and its 200-day moving average of $176.90, confirming a sustained bullish trend. The 14-day relative strength index registers at 77.3, placing the stock in overbought territory and suggesting elevated buying pressure. AZN's beta of 0.168 per Massive/Polygon data indicates extremely low volatility relative to the broader market, consistent with its defensive healthcare sector positioning. Average daily trading volume stands at approximately 5.47 million shares, supporting adequate liquidity for the company's market capitalization of approximately $279.9 billion.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC currently trades at a price-to-earnings ratio of 33.06, representing a premium valuation relative to the broader healthcare sector, per SID market data. The PEG ratio stands at 4.53, suggesting that the stock's earnings growth rate does not fully justify its elevated P/E multiple at current levels. The price-to-book ratio of 6.24 further reflects a substantial premium to book value, consistent with the market's pricing of AstraZeneca's extensive oncology and biopharmaceutical pipeline. According to SEC filings, the company offers a dividend yield of approximately 1.56%, providing modest income for shareholders. With a market capitalization of roughly $279.9 billion, AstraZeneca ranks among the largest global pharmaceutical companies. The current valuation metrics indicate the market is pricing in continued robust revenue growth from the company's diversified therapeutic portfolio and late-stage clinical pipeline assets.
Smart Money Activity for AZN
AstraZeneca PLC registers a composite smart money score of 59 out of 100, reflecting a neutral overall signal per SID market data. Institutional positioning scores a perfect 25 out of 25, indicating strong conviction among large fund managers and institutional investors according to 13F institutional filings. Insider activity scores 12.5 out of 25, with SEC Form 4 filings revealing two insider transactions over the past 90 days, both of which were purchases with zero sells recorded during the period. This insider buying pattern suggests internal confidence in the company's forward prospects. Dark pool activity scores a relatively modest 9.5 out of 25, indicating below-average off-exchange institutional trading interest. Congressional trading activity registers at 12 out of 25, reflecting moderate engagement from disclosed congressional portfolios. The divergence between maximum institutional conviction and more subdued dark pool activity creates a mixed but slightly constructive smart money profile for AZN shareholders to monitor.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC has delivered substantial earnings surprises in its most recent reported quarters, according to company earnings reports. The quarter reported on October 30, 2026, posted actual earnings per share of $2.79 against analyst estimates of $1.44, resulting in a positive surprise of $1.35, or approximately 93.8% above consensus. Similarly, the quarter reported on July 27, 2026, recorded actual EPS of $2.63 versus estimates of $1.52, delivering a $1.11 positive surprise. Looking ahead, analysts project EPS of $1.44 for the quarter with results expected on July 28, 2026, and $1.35 for the quarter scheduled for November 5, 2026, per analyst estimates. The consistent pattern of significantly exceeding consensus expectations across consecutive quarters highlights potential conservatism in current street estimates. Investors are closely monitoring whether AstraZeneca can sustain this trajectory of outperformance in upcoming reporting periods.
Wall Street Analyst Ratings for AZN
Wall Street analyst sentiment on AstraZeneca PLC remains divided, per SID consensus data. Berenberg Bank issued a Buy rating on July 13, 2026, representing the most recent analyst action on the stock. Jefferies has maintained a consistently bullish stance, reiterating Buy ratings on both June 26 and June 9, 2026, according to Wall Street analyst reports. Conversely, Deutsche Bank has taken a bearish position, issuing Sell ratings on June 26 and June 11, 2026, creating a notable divergence among major sell-side institutions. The opposing views between Jefferies and Deutsche Bank highlight the ongoing debate surrounding AZN's valuation, particularly given the stock's P/E of 33.06 and its 127.27% one-year price appreciation. The split consensus reflects differing assessments of whether AstraZeneca's robust earnings trajectory and pipeline developments justify the current premium valuation or whether the stock's overbought technical positioning warrants caution at these elevated levels.
